|作者：||Han Tao, Yang Xiaodan, Zhang Yue, Li Gao, Liu Lu, Chen Tingsong, Zheng Zhendong|
1Department of Oncology, Cancer Center, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.
2Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
3Department of Invasive Technology, The Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China.
|刊名：||Bioscience trends, 2019, Vol.13 (5), pp.374-381|
|关键词：||DEB-TACE; TACE; Liver cancer; Objective response rate; Safety; Survival;|
|原始语种摘要：||Transcatheter arterial chemoembolization (TACE) plays an important role in the treatment of unresectable liver cancer. We conducted this meta-analysis to compare the clinical safety and efficacy of conventional TACE (C-TACE) and drug-eluting beads (DEB)-TACE. A search for those procedures was performed using the PubMed, EMBASE, and Cochrane Library databases. A meta-analysis of patients who underwent C-TACE or DEB-TACE was conducted. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Of 334 studies, 30 were analyzed. The complete response rate, disease control rate, objective response rate, 3-year survival rate, and non-response rate were significantly higher in patients who underwent DEB-TACE than those in patients who underwent C-TACE. The 1-year survival rate, 2-year... survival rate, 30-day mortality rate, complete response rate, disease control rate, complete necrosis rate, non-response rate, objective response rate, progressive disease rate, and recurrence did not differ significantly between patients who underwent C-TACE and patients who underwent DEB-TACE. Patients who undergo DEB-TACE might have a higher complete response rate, disease control rate, and 3-year survival rate than patients who undergo C-TACE. Safety did not differ significantly between C-TACE and DEB-TACE.|